Results 141 to 150 of about 149,947 (326)
Intracranial arteriosclerosis is not associated with cerebral amyloid deposition
BACKGROUND Intracranial arteriosclerosis and cerebral amyloid beta (Aβ) are both involved in the etiology of Alzheimer's disease (AD) dementia, but the direct link between these two pathologies remains elusive.
Anna M. Streiber +4 more
doaj +1 more source
The Role of Progenitor Cells in the Pathogenesis of Arteriosclerosis
The increasing incidence of arteriosclerosis has become a significant global health burden. Arteriosclerosis is characterized by the thickening and hardening of arterial walls, which can lead to the narrowing or complete blockage of blood vessels ...
Yuesheng Zhang +6 more
doaj +1 more source
Autopsy findings in cases of fatal COVID‐19 vaccine‐induced myocarditis
Abstract COVID‐19 vaccines have been linked to myocarditis, which, in some circumstances, can be fatal. This systematic review aims to investigate potential causal links between COVID‐19 vaccines and death from myocarditis using post‐mortem analysis.
Nicolas Hulscher +3 more
wiley +1 more source
Arteriosclerosis in a Dog [PDF]
n ...
openaire +2 more sources
Under chronic stress, female rats are more susceptible to developing depression compared to male rats. EGCG inhibits CUMS‐induced pyroptosis in rat liver and brain tissue by inhibiting the activation of the NF‐кB/caspase‐1 signaling pathway, reducing liver damage, and improving depression‐like behaviors in rats.
Guixian Wu +15 more
wiley +1 more source
BackgroundPeripheral arteriosclerosis is caused by any atherosclerosis outside the heart and brain. However, the underlying biological mechanisms are not fully understood.
Qian Ye, Yilin Zhou, Kai Xu, Zhili Jiang
doaj +1 more source
Arteriosclerosis and Hypothyroidism: Observations on Their Possible Interrelationship [PDF]
Maurice Bruger, J. A. Rosenkrantz
openalex +1 more source
Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
PROTACs are reshaping drug discovery through targeted protein degradation. Clinical programs now extend to prostate, breast, lung, hematologic, and solid tumors, with key targets including AR, ER, BTK, STAT3, Bcl‐xL, BRD9, Kras, and so on. These degraders overcome resistance, broaden therapeutic scope, and provide solutions for “undruggable” proteins ...
Gang Fan +9 more
wiley +1 more source

